Mangoceuticals Inc (MGRX)

$0.38 +0.01 (1.78%)
Market Cap 6.46M
Revenue (ttm) 460,000.00
Net Income (ttm) -20.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,486.96%
Debt to Equity Ratio 0.00
Volume 329,800
Avg Vol 1,387,986
Day's Range N/A - N/A
Shares Out 17.17M
Stochastic %K 87%
Beta 2.27
Analysts Strong Buy
Price Target N/A

Company Profile

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone...

Industry: Health Information Services
Sector: Healthcare
Phone: 214 242 9619
Address:
17130 N. Dallas Parkway, Suite 240, Dallas, United States
JasmyMoonGuide
JasmyMoonGuide Jun. 25 at 11:50 PM
$MGRX it would be nice to rebound to $.38 before overnight trading
0 · Reply
2jmoney
2jmoney Jun. 25 at 2:27 PM
$MGRX here comes trip 10 to .50. Jacob delivers we run to .84
0 · Reply
JasmyMoonGuide
JasmyMoonGuide Jun. 24 at 6:38 PM
$MGRX No post here since 2 am? Yall alive? We still holding or what!?
0 · Reply
npl7
npl7 Jun. 24 at 7:07 AM
$MGRX added 5.6K before closing. Need more volume but 0.4 that’s the point where volume will go up. Let’s get it
0 · Reply
topstockalerts
topstockalerts Jun. 24 at 12:50 AM
$MGRX feels like buyers are slowly taking control here
1 · Reply
StonkMethod
StonkMethod Jun. 23 at 11:06 PM
$MGRX
1 · Reply
Drugdoctor
Drugdoctor Jun. 23 at 11:05 PM
$MGRX the ask is so thin all the way back up to .39. If the players want to take it back to .50, won't take a lot of ask slapping to get it there.
0 · Reply
npl7
npl7 Jun. 23 at 10:51 PM
$MGRX 2k added
1 · Reply
JasmyMoonGuide
JasmyMoonGuide Jun. 23 at 10:43 PM
$MGRX damn...here comes the dump. Question is how low will it go this time.
1 · Reply
JasmyMoonGuide
JasmyMoonGuide Jun. 23 at 10:38 PM
$MGRX nees to Crack $.40 I cant go through another -30% overnight. Stop selling and hit the buy button
0 · Reply
Latest News on MGRX
Mangoceuticals Quarterly report: Q1 2026

May 19, 2026, 7:00 AM EDT - 5 weeks ago

Mangoceuticals Quarterly report: Q1 2026

Mangoceuticals Annual report: Q4 2025

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Mangoceuticals Annual report: Q4 2025

Why Is Mangoceuticals, Inc. Stock (MGRX) Up Today?

2026-03-23T13:27:03.000Z - 3 months ago

Why Is Mangoceuticals, Inc. Stock (MGRX) Up Today?

Mangoceuticals files civil lawsuit against Clarity Ventures

2026-03-17T20:15:36.000Z - 3 months ago

Mangoceuticals files civil lawsuit against Clarity Ventures

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mar 17, 2026, 4:00 PM EDT - 3 months ago

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals announces patent filing for MGX-0024

2026-03-06T21:10:53.000Z - 4 months ago

Mangoceuticals announces patent filing for MGX-0024

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mar 6, 2026, 4:00 PM EST - 4 months ago

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Feb 23, 2026, 4:05 PM EST - 4 months ago

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Here’s Why Mangoceuticals Stock (MGRX) Rocketed Today

2026-02-20T14:09:28.000Z - 4 months ago

Here’s Why Mangoceuticals Stock (MGRX) Rocketed Today

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Feb 19, 2026, 4:05 PM EST - 4 months ago

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Mangoceuticals Registration statement: Registration Filing

Jan 23, 2026, 7:00 AM EST - 5 months ago

Mangoceuticals Registration statement: Registration Filing

Mangoceuticals files to sell 2.64M shares of common stock for holders

2026-01-13T22:35:14.000Z - 5 months ago

Mangoceuticals files to sell 2.64M shares of common stock for holders

Mangoceuticals Registration statement: Registration Filing

Jan 13, 2026, 7:00 AM EST - 5 months ago

Mangoceuticals Registration statement: Registration Filing

Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements

Dec 19, 2025, 10:38 AM EST - 6 months ago

Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements

Mangoceuticals, Cube Group partner for up to $100M Solana-focused DAT strategy

2025-12-19T12:35:43.000Z - 6 months ago

Mangoceuticals, Cube Group partner for up to $100M Solana-focused DAT strategy

Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

Dec 19, 2025, 7:30 AM EST - 6 months ago

Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

Mangoceuticals announces $2.5M registered direct, private placements

2025-12-18T13:41:44.000Z - 6 months ago

Mangoceuticals announces $2.5M registered direct, private placements

Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules

Dec 18, 2025, 8:30 AM EST - 6 months ago

Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules

Mangoceuticals Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 8 months ago

Mangoceuticals Quarterly report: Q3 2025

Investors Flee Mangoceuticals Stock (MGRX) after Eli Lilly and Novo Nordisk Deny Partnership

2025-11-14T10:17:04.000Z - 8 months ago

Investors Flee Mangoceuticals Stock (MGRX) after Eli Lilly and Novo Nordisk Deny Partnership

LLY NVO

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Nov 13, 2025, 7:37 PM EST - 8 months ago

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Novo denies partnership with Mangoceuticals on obesity drug, Reuters says

2025-11-13T19:35:28.000Z - 8 months ago

Novo denies partnership with Mangoceuticals on obesity drug, Reuters says

LLY NVO

Eli Lilly says ‘no affiliation’ with Mangoceuticals

2025-11-13T19:30:24.000Z - 8 months ago

Eli Lilly says ‘no affiliation’ with Mangoceuticals

LLY NVO

Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs

Nov 13, 2025, 2:04 PM EST - 8 months ago

Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs

LLY NVO

Mangoceuticals Stock (MGRX) Soars on Deal to Sell Obesity Drugs for Eli Lilly, Novo Nordisk

2025-11-13T14:10:42.000Z - 8 months ago

Mangoceuticals Stock (MGRX) Soars on Deal to Sell Obesity Drugs for Eli Lilly, Novo Nordisk

AZN LLY MTSR NVO PFE

Mangoceuticals partner with Eli Lilly, Novo, provide access to Zepbound, Wegovy

2025-11-13T12:25:27.000Z - 8 months ago

Mangoceuticals partner with Eli Lilly, Novo, provide access to Zepbound, Wegovy

LLY NVO

Mangoceuticals partners with Lilly, Novo Nordisk to sell weight-loss drugs

Nov 13, 2025, 7:15 AM EST - 8 months ago

Mangoceuticals partners with Lilly, Novo Nordisk to sell weight-loss drugs

LLY NVO

Mangoceuticals Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Mangoceuticals Quarterly report: Q2 2025

Mangoceuticals files $150M mixed securities shelf

2025-06-13T20:35:18.000Z - 1 year ago

Mangoceuticals files $150M mixed securities shelf

Mangoceuticals Registration statement: Registration Filing

Jun 13, 2025, 8:00 AM EDT - 1 year ago

Mangoceuticals Registration statement: Registration Filing

Mangoceuticals files to sell 4.46M shares of common stock for holders

2025-05-30T20:35:11.000Z - 1 year ago

Mangoceuticals files to sell 4.46M shares of common stock for holders

Mangoceuticals Registration statement: Registration Filing

May 30, 2025, 8:00 AM EDT - 1 year ago

Mangoceuticals Registration statement: Registration Filing

Mangoceuticals shares results from field studies on MGX-0024

2025-05-27T13:15:43.000Z - 1 year ago

Mangoceuticals shares results from field studies on MGX-0024

Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

May 27, 2025, 9:00 AM EDT - 1 year ago

Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

Mangoceuticals Quarterly report: Q1 2025

May 15, 2025, 12:00 AM EDT - 1 year ago

Mangoceuticals Quarterly report: Q1 2025

ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market

Apr 28, 2025, 9:36 AM EDT - 1 year ago

ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market

CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Apr 26, 2025, 10:54 AM EDT - 1 year ago

CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Apr 25, 2025, 10:26 AM EDT - 1 year ago

ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Mangoceuticals enters into agreement to acquire assets of Smokeless Technology

2025-04-25T13:07:55.000Z - 1 year ago

Mangoceuticals enters into agreement to acquire assets of Smokeless Technology

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

Apr 25, 2025, 9:00 AM EDT - 1 year ago

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape

Apr 22, 2025, 1:55 PM EDT - 1 year ago

CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape

Mangoceuticals enters master distribution agreement for Diabetinol rights

2025-03-25T18:22:34.000Z - 1 year ago

Mangoceuticals enters master distribution agreement for Diabetinol rights

Mangoceuticals Annual report: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Mangoceuticals Annual report: Q4 2024

Mangoceuticals Proxy statement: Proxy Filing

Feb 18, 2025, 7:00 AM EST - 1 year ago

Mangoceuticals Proxy statement: Proxy Filing

Mangoceuticals Proxy statement: Proxy Filing

Feb 6, 2025, 7:00 AM EST - 1 year ago

Mangoceuticals Proxy statement: Proxy Filing

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Feb 3, 2025, 8:30 AM EST - 1 year ago

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Dec 19, 2024, 5:33 PM EST - 1 year ago

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Mangoceuticals Quarterly report: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Mangoceuticals Quarterly report: Q3 2024

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

Oct 21, 2024, 5:10 PM EDT - 1 year ago

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024

Oct 18, 2024, 8:45 AM EDT - 1 year ago

Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024

MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN

Oct 11, 2024, 5:15 PM EDT - 1 year ago

MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

Oct 3, 2024, 8:30 AM EDT - 1 year ago

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

Oct 1, 2024, 7:30 AM EDT - 1 year ago

MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

Mangoceuticals Registration statement: Registration Filing

Aug 16, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Registration statement: Registration Filing

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

Aug 15, 2024, 9:25 AM EDT - 2 years ago

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

Mangoceuticals Quarterly report: Q2 2024

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Mangoceuticals Quarterly report: Q2 2024

Mangoceuticals Earnings release: Q2 2024

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Mangoceuticals Earnings release: Q2 2024

MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide

Aug 9, 2024, 8:15 AM EDT - 2 years ago

MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide

MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market

Aug 8, 2024, 8:30 AM EDT - 2 years ago

MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market

MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology

Jul 24, 2024, 8:15 AM EDT - 2 years ago

MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology

Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access

Jul 18, 2024, 4:05 PM EDT - 2 years ago

Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

Jul 16, 2024, 8:20 AM EDT - 2 years ago

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Jul 12, 2024, 1:30 PM EDT - 2 years ago

MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets

Jul 11, 2024, 8:15 AM EDT - 2 years ago

MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Jun 6, 2024, 8:30 AM EDT - 2 years ago

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

Jun 4, 2024, 4:00 PM EDT - 2 years ago

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets

May 28, 2024, 8:30 AM EDT - 2 years ago

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

May 23, 2024, 8:30 AM EDT - 2 years ago

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications

May 21, 2024, 8:30 AM EDT - 2 years ago

MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

May 16, 2024, 4:40 PM EDT - 2 years ago

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

Mangoceuticals Proxy statement: Proxy Filing

May 16, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Proxy statement: Proxy Filing

Mangoceuticals Quarterly report: Q1 2024

May 15, 2024, 6:00 PM EDT - 2 years ago

Mangoceuticals Quarterly report: Q1 2024

Mangoceuticals Registration statement: Registration Filing

May 6, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Registration statement: Registration Filing

Mangoceuticals Proxy statement: Proxy Filing

May 6, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Proxy statement: Proxy Filing

Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

May 2, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Mangoceuticals Registration statement: Registration Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Registration statement: Registration Filing

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

Apr 12, 2024, 8:45 AM EDT - 2 years ago

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

Mangoceuticals Annual report: Q4 2023

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Annual report: Q4 2023

MangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment

Mar 12, 2024, 9:00 AM EDT - 2 years ago

MangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment

Mangoceuticals Proxy statement: Proxy Filing

Mar 1, 2024, 7:00 AM EST - 2 years ago

Mangoceuticals Proxy statement: Proxy Filing

MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth

Feb 20, 2024, 9:00 AM EST - 2 years ago

MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth

Mangoceuticals Proxy statement: Proxy Filing

Feb 20, 2024, 7:00 AM EST - 2 years ago

Mangoceuticals Proxy statement: Proxy Filing

MANGORX TO OFFER THE BIG GAME'S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE

Feb 6, 2024, 9:00 AM EST - 2 years ago

MANGORX TO OFFER THE BIG GAME'S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE

MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

Feb 5, 2024, 8:50 AM EST - 2 years ago

MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

MangoRx's Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11

Jan 19, 2024, 8:00 AM EST - 2 years ago

MangoRx's Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11

Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering

Dec 15, 2023, 10:39 AM EST - 2 years ago

Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

Dec 13, 2023, 7:30 AM EST - 2 years ago

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

Mangoceuticals Registration statement: Registration Filing

Dec 12, 2023, 7:00 AM EST - 2 years ago

Mangoceuticals Registration statement: Registration Filing

Mangoceuticals Registration statement: Registration Filing

Dec 11, 2023, 7:00 AM EST - 2 years ago

Mangoceuticals Registration statement: Registration Filing

Mangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin America

Dec 6, 2023, 8:00 AM EST - 2 years ago

Mangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin America

Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider

Nov 29, 2023, 8:30 AM EST - 2 years ago

Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider

Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx

Nov 16, 2023, 8:30 AM EST - 2 years ago

Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx

Mangoceuticals, Inc. Launches Charitable Initiative in Support of Men's Health Awareness Month

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Mangoceuticals, Inc. Launches Charitable Initiative in Support of Men's Health Awareness Month

JasmyMoonGuide
JasmyMoonGuide Jun. 25 at 11:50 PM
$MGRX it would be nice to rebound to $.38 before overnight trading
0 · Reply
2jmoney
2jmoney Jun. 25 at 2:27 PM
$MGRX here comes trip 10 to .50. Jacob delivers we run to .84
0 · Reply
JasmyMoonGuide
JasmyMoonGuide Jun. 24 at 6:38 PM
$MGRX No post here since 2 am? Yall alive? We still holding or what!?
0 · Reply
npl7
npl7 Jun. 24 at 7:07 AM
$MGRX added 5.6K before closing. Need more volume but 0.4 that’s the point where volume will go up. Let’s get it
0 · Reply
topstockalerts
topstockalerts Jun. 24 at 12:50 AM
$MGRX feels like buyers are slowly taking control here
1 · Reply
StonkMethod
StonkMethod Jun. 23 at 11:06 PM
$MGRX
1 · Reply
Drugdoctor
Drugdoctor Jun. 23 at 11:05 PM
$MGRX the ask is so thin all the way back up to .39. If the players want to take it back to .50, won't take a lot of ask slapping to get it there.
0 · Reply
npl7
npl7 Jun. 23 at 10:51 PM
$MGRX 2k added
1 · Reply
JasmyMoonGuide
JasmyMoonGuide Jun. 23 at 10:43 PM
$MGRX damn...here comes the dump. Question is how low will it go this time.
1 · Reply
JasmyMoonGuide
JasmyMoonGuide Jun. 23 at 10:38 PM
$MGRX nees to Crack $.40 I cant go through another -30% overnight. Stop selling and hit the buy button
0 · Reply
StonkMethod
StonkMethod Jun. 23 at 10:36 PM
$MGRX
0 · Reply
The_Assassin
The_Assassin Jun. 23 at 10:32 PM
$MGRX looks interesting
0 · Reply
Alonso1135
Alonso1135 Jun. 23 at 10:32 PM
$MGN $MGRX
0 · Reply
topstockalerts
topstockalerts Jun. 23 at 6:28 PM
$MGRX buyers are treating every dip like an invitation.
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 23 at 5:59 PM
$EHGO Ripping , $BLZE new high of day $ATLN squeeze? $FOFO from scanners great move today $MGRX Too 💵👍
0 · Reply
letsgopeeps
letsgopeeps Jun. 23 at 5:46 PM
$MGRX Who is this clown?
0 · Reply
thegoodcall
thegoodcall Jun. 23 at 5:09 PM
$MGRX looking good for huge run. Could go %100. It could be on the first top gainers EOD. Like $CIIT $ADTX $ATLN $MGN
1 · Reply
Arthur86
Arthur86 Jun. 23 at 3:15 PM
$MGRX
1 · Reply
letsgopeeps
letsgopeeps Jun. 23 at 2:53 PM
$MGRX Yeah. For about 33 minutes
0 · Reply
Denk333
Denk333 Jun. 23 at 1:35 PM
$MGRX wasn’t this like 60% AH yesterday???
0 · Reply
makesomemoneybro123
makesomemoneybro123 Jun. 23 at 1:22 PM
$MGRX I do understand market is bleeding today, but this one hasn't even tried to show some up move...
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Jun. 23 at 1:15 PM
🌅 Watchlist part 2 ✅ $GITS $1.70 support, if above $2.00, has potential to $2.30/$2.60 ✅ $VTAK $1.10 support, if above $1.30, has potential to $1.50/$1.60 ✅ $ORIS low $3 support, if above $3.30, has potential to $3.50/$3.80 ✅ $ICCM low $6 support, if above $6.60, has potential to $7/$7.40 ✅ $MGRX low $0.20 support, if above $0.30, has potential to $0.40/$0.50 🚨 The above tickers are not ideal for swing accumulation at current prices 🚨 ✅ Ideal long entry near current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GREEN, not GREED 😎😎
0 · Reply